Rapport Therapeutics, Inc. Common Stock
RAPPNASDAQHealthcareBiotechnology
Previous close
$48.24
+$0.39 · +0.82%
RAPP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
38
Expensive
Momentum
74
Gaining
Sentiment
63
Bullish
Risk resilience
59
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteRapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Abraham N. Ceesay
- Listed since
- Jun 7, 2024
- Employees
- 84
Market position
Day range
Current $48.24
52-week range
Current $48.24
- Open
- $48.35
- Previous close
- $47.85
- Volume
- 140.87K
- 0.4× average
- Average volume
- 355.71K
- Average daily volume
- Market cap
- 2.31B USD
- Beta
- 0.97
- Market reference 1
- 50-day average
- $42.0591
- +14.70% above average
- 200-day average
- $33.6165
- +43.50% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -15.87×
- P/B (TTM)
- 5.41×
- P/S (TTM)
- 115.36×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 100.00%
- Operating margin
- -767.58%
- Net margin
- -685.80%
Financial health
- Debt / equity
- 0.02×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | — | — | — | 15K USD |
| Gross profit | — | — | — | −15K USD |
| Research and development | 94.79M USD | 60.94M USD | 28M USD | 9.12M USD |
| Selling, general, and administrative | 30.31M USD | 22.12M USD | 8.18M USD | 1.37M USD |
| Operating expenses | 125.1M USD | 83.06M USD | 36.18M USD | 10.35M USD |
| Interest income | 13.62M USD | 12.14M USD | 2.53M USD | — |
| Interest expense | — | — | — | 285K USD |
| Depreciation and amortization | 1.02M USD | 839K USD | 112K USD | 15K USD |
| Operating income | −125.1M USD | −83.06M USD | −36.18M USD | −10.37M USD |
| Net income | −111.48M USD | −78.31M USD | −34.79M USD | −10.65M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -2.86
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$62.80
30.18% upsidePrice history unavailable
High $75.00Average $62.80Low $52.00Recent analyst actions
RAPP news
RAPP peers
Continue in GoAI
Research RAPPresearch.disclaimer